Zura Bio Limited Revenue and Competitors
Estimated Revenue & Valuation
- Zura Bio Limited's estimated annual revenue is currently $2.1M per year.
- Zura Bio Limited's estimated revenue per employee is $55,066
Employee Data
- Zura Bio Limited has 38 Employees.
- Zura Bio Limited grew their employee count by 46% last year.
Zura Bio Limited's People
Name | Title | Email/Phone |
---|
Zura Bio Limited Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 5 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 4 | -50% | N/A | N/A |
#6 | $0.7M | 8 | 0% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 17 | 31% | N/A | N/A |
What Is Zura Bio Limited?
Zura Bio Limited is a clinical-stage biotechnology company advancing immunology assets into Phase 2 development programs, including ZB-168 and torudokimab. ZB-168 is an anti IL7R α inhibitor that has the potential to impact diseases driven by IL7 and TSLP biological pathways. Zura aims to develop a portfolio of therapeutic indications for ZB-168 which build on existing Phase 1b data in Type 1 Diabetes demonstrating a favorable safety profile and strong biological rationale. Torudokimab is a fully human, high affinity monoclonal antibody that neutralizes IL33 and is currently at the Phase 2 clinical development stage. Zura Bio is headquartered in San Diego, CA with team members in the UK and USA.
keywords:N/AN/A
Total Funding
38
Number of Employees
$2.1M
Revenue (est)
46%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $9.8M | 38 | -21% | N/A |
#2 | $4.2M | 38 | -14% | $2.2M |
#3 | $4.4M | 38 | N/A | N/A |
#4 | $15.7M | 38 | -3% | N/A |
#5 | $7.6M | 38 | 12% | N/A |